New radioactive tracer could spot hidden tumors
NCT ID NCT05799274
First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This early-stage trial tests a radioactive imaging agent called RAD301 in 9 people: healthy volunteers and patients with pancreatic, lung, esophageal, cervical, endometrial, or ovarian cancer. The goal is to see how safe it is and how it travels through the body. If it works, it might help doctors see tumors more clearly on scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RAD301 (a radioactive imaging agent)
- What this could lead to
- If successful, this could lead to a safer way to detect and monitor certain cancers using PET scans.
- What could go wrong
- This is a very early Phase 1 trial with only 9 participants, so results may not apply broadly. The main goal is safety, not effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Montefiore Medical Center
RECRUITINGThe Bronx, New York, 10461, United States
-
United Theranostics
TERMINATEDPrinceton, New Jersey, 08540, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Blood and gut clues may flag pancreatic cancer risk early